<DOC>
	<DOCNO>NCT02546739</DOCNO>
	<brief_summary>This study aim evaluate safety , efficacy duration response CD19 Chimeric Antigen Receptor ( CAR ) redirect autologous T-cells patient high risk , relapse CD19+ haematological malignancy .</brief_summary>
	<brief_title>Immunotherapy With CD19 CAR T-cells B-Cell Lymphoma , ALL CLL</brief_title>
	<detailed_description>This multi-centre , non-randomised , open label Phase I clinical trial Advanced Therapy Investigational Medicinal Product name CD19 Chimeric Antigen Receptor ( CAR ) T-cells ( CD19 CAR T-cells ) patient high risk , relapse CD19+ haematological malignancy ( Leukemia lymphoma ) . Following informed consent registration trial , patient undergo unstimulated leukapheresis generation CD19 CAR T-cells . Patients receive CD19CAR T-cells follow lymphodepleting chemotherapy . The study evaluate safety , efficacy duration response CD19 CAR T-cells patient high risk relapse CD19+ malignancy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . Relapsed refractory B cell derive acute lymphoblastic leukemia ( ALL ) , chronic lymphoblastic leukemia ( CLL ) nonhodgkin lymphoma . 2 . KPS &gt; 60 . 3 . Life expectancy &gt; 3 month . 4 . Gender unlimited , age 18 year 70 year . 5 . CD19 expression must detect great 15 % malignant cell immunohistochemistry great 30 % flow cytometry . 6 . Patients fail least one line standard treatment . 7 . No serious mental disorder . 8 . Patients must adequate cardiac function ( cardiac disease , LVEF≥40 % ) , adequate pulmonary function indicate room air oxygen saturation &gt; 94 % , adequate renal function ( Cr≤133umol/L ) . 9 . No serious disease ( autoimmune disease , immunodeficiency etc. ) . 10 . No tumor . 11 . Patients volunteer participate research . 12 . Patients history allogeneic stem cell transplantation eligible least 100 day posttransplant , evidence active GVHD longer take immunosuppressive agent least 30 day prior 1 . KPS &lt; 50 . 2 . Patients allergic cytokine . 3 . Central nervous system leukemia within 28 day . 4 . Uncontrolled active infection . 5 . Acute chronic GVHD . 6 . Treated T cell inhibitor . 7 . Pregnancy nursing female . 8 . HIV/HBV/HCV Infection . 9 . Other situation think improper research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>CAR T</keyword>
</DOC>